🇺🇸 FDA
Patent

US 11834499

Claudin18 antibodies and methods of treating cancer

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11834499 (Claudin18 antibodies and methods of treating cancer) held by The Regents of the University of California expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
99
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K47/68031, A61K47/6849